One hundred and eighty nine participants were enrolled with 161 (85%) being PLWH. Among participants without previous known COVID-19, median aSAb levels were significantly lower in PLWH who received CoronaVac compared to BNT162b2 (32 U/mL vs. 587 U/mL, p < 0.001), with similar results in...
This comparative effectiveness study compares the estimated effectiveness of coadministration of the BNT162b2 BA.4/5 bivalent mRNA COVID-19 vaccine and
161 H. Wickham ggplot2: Elegant Graphics for Data Analysis Springer-Verlag (2016) Google Scholar 162 A. Kassambara ggpubr: 'ggplot2' Based Publication Ready Plots https://rpkgs.datanovia.com/ggpubr/ (2023) Google Scholar 163 Y. Tang, M. Horikoshi, W. Li ggfortify: Unified Interface to...
Background To date, globally considered, the literature suggests that AIRD may be at higher risk of infection and death due to COVID19 compared to the general population. Vaccination against SARS-CoV-2 reduces the risk of hospitalization and mortality. However, immunological alteration associated ...
This retrospective cohort study assesses incidence of breakthrough COVID-19 and hospitalization with COVID-19 pneumonia or death among adults who received
A US national vaccine safety surveillance system (VAERS) found that, out of 42,504 AEs in 5–11-year-old children after two doses of BNT161b2, 57.5 % and 40.9 % reported local and systemic reactions, respectively [28], [32]. Walter et al. [21] also observed a greater prevalence of...
Download: Download high-res image (161KB) Download: Download full-size image Fig. 2. Study design. 2.4. Hybrid immunity vs. vaccine-induced immunity We divided all study participants into those with proofs of preceding SARS-CoV-2 infection and those SARS-CoV-2 naive. A positive result of ...
At T1, 161 participants (97.6%) showed seroconversion with a median of IgG values of 468.8 AU/mL (IQR: 200.4–774.3 AU/mL). By T2, all subjects maintained a positive result, with the median anti-SARS-CoV-2 Spike IgG concentration increasing to 6191.6 AU/mL (IQR: 3666.7–10,800.8 AU/...
The BNT162b2 mRNA vaccine (BioNTech/Pfizer), the first to receive authorization, was widely used in the mass vaccination campaign in Italy. Healthcare workers were identified as a priority group for vaccination, but few studies have assessed its reactogenicity among the young working age population...